University of Wisconsin, Madison
The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth. Participants will: * have bone marrow collected using a needle * undergo a salivary gland ultrasound * complete questionnaires * receive an injection of the bone marrow cells into a salivary gland
Xerostomia
Graft-versus-host-disease
Sjogren's Disease
Mesenchymal Stromal Cells (MSC) Dose Level 0
Mesenchymal Stromal Cells (MSC) Dose Level 1
PHASE1
This single-center phase I dose-escalation with expansion cohort, open label, non-randomized, non-placebo controlled, single group assignment study will assess the safety and tolerability of mesenchymal stromal cells (MSCs) for treatment of xerostomia, focusing on xerostomia with inflammatory etiology (e.g., Sjögren's disease \[SjD\], graft-versus-host disease \[GVHD\]). An initial cohort of subjects (n=6) will receive a unilateral injection of MSCs at dose level 0. If unilateral treatment is tolerated, a dose escalation cohort (n=8-18) will receive bilateral injection of MSCs. Dose escalation will proceed using a standard 3+3 design and once the recommended phase II dose (RP2D) is defined, 12 additional patients will be accrued to the expansion phase. Following the completion of screening/baseline procedures, eligible participants will undergo bone marrow aspiration in order to obtain MSCs. The MSC investigational product will be injected into one or both submandibular glands under local anesthesia at the interventional visit.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 36 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia |
Actual Study Start Date : | 2024-10 |
Estimated Primary Completion Date : | 2028-11 |
Estimated Study Completion Date : | 2028-11 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 90 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Wisconsin
Madison, Wisconsin, United States, 53705